| Title | Publication Date | Price |
|---|---|---|
Bioinformatics Partnering Terms and Agreements3rd Edition Provides comprehensive insight into bioinformatics partnering deals and agreements entered into by leading healthcare companies. | March 2013 | £1,850 |
Partnering Deals and Alliances with Big Pharma6th Edition Provides comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. | February 2013 | £1,980 |
Vaccine Partnering Terms and Agreements4th Edition Provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. | January 2013 | £1,780 |
Partnering and M&A YearbookYearbook 2012 Provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2011. | January 2012 | £1,910 |
Preparing Health Technology Submissions for Pharmaceutical ProductsMeeting Formulary Submission Requirements for New Product Assessments and Disease Area & Therapeutic Class Reviews Considers how manufacturers should respond to emerging evidentiary and analytical standards | March 2006 | £995 |
Directory of Business Development & Licensing Contacts 2006The Worldwide Pharmaceutical Industry Over 1,300 business development opportunities listed... | February 2006 | n/a |
Health Economics in the Drug Life CycleAchieving success in drug discovery, development, reimbursement and marketing A 75,000 word report from Urch Publishing identifies the clusters of health economic activities which should accompany drug development from discovery through to marketing approval and then market reimbursement, market entry and the support of the product through the product life cycle. | January 2003 | £695 |
Little Black Book of Pharma Marketing, The | March 2002 | n/a |
eDetailing - A Strategic Analysis of Implementation and ROIComprehensive insight into eDetailing including regulations, technologies, companies and strategic recommendations. | September 2001 | £495 |
Customer Driven Pharmaceutical MarketingDeveloping & exploiting profitable relationship Tackles the new paradigm and argues that companies should focus on the end user more than ever and build long term relationships. | March 2001 | £125 |
Patient Groups and the Global Pharmaceutical IndustryPatient advocacy groups have emerged as a key customer for the industry as they potentially hold a great deal of power and influence. Such 'added value' approaches are becoming common-place and the advent of abundant and well run patient advocacy groups has placed such company-patient group alliances to the top of the strategy agenda | January 2000 | £200 |
Successful LicensingNegotiating & Drafting Optimum Pharmaceutical Deals This report provides a comprehensive guide to the business development processes involved in assessing product opportunities, negotiating deals and implementing crucial partnerships. | February 1999 | n/a |